Shanghai Ovarian Cancer and Family Care Project
NCT06118307 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3546
Last updated 2023-11-07
Summary
Ovarian cancer is the most lethal gynaecological malignancy, but its incidence in the general population is low. Due to the lack of effective prevention and successful screening approaches, most cases are diagnosed at advanced stages, leading to poor prognosis. In order to address the research requirements pertaining to ovarian cancer, the Shanghai Ovarian Cancer and Family Care Project was established. This initiative offers hospital-based resources for investigating ovarian cancer and high-risk populations. The project comprises an on-going ovarian cancer cohort, a high-risk population cohort, and a healthy population cohort. By leveraging these comprehensive cohorts, the project provides a unique platform for in-depth studies on the detection, prevention, early diagnosis, treatment, and prognosis of ovarian cancer.
Conditions
Sponsors & Collaborators
-
Shanghai First Maternity and Infant Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-01-01
- Primary Completion
- 2028-10-13
- Completion
- 2028-10-13
Countries
- China
Study Locations
More Related Trials
-
Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer
NCT03180177 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer
NCT05371301 ·Status: UNKNOWN ·Phase: PHASE3
-
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
NCT05737303 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery
NCT03373058 ·Status: UNKNOWN ·Phase: PHASE3
-
Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients
NCT06182917 ·Status: RECRUITING
-
Diagnosis of Epithelial Ovarian Cancer Using Ovarian Cancer Score (OCS) Test
NCT06366997 ·Status: COMPLETED
-
Survival Outcomes of Ovarian Malignancies in Chinese Population
NCT03291262 ·Status: UNKNOWN
-
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
NCT04807166 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Culture of Advanced or Recurrent Ovarian Cancer Organoids and Drug Screening
NCT05290961 ·Status: UNKNOWN
-
Individualized Health Management of Epithelial Ovarian Cancer: A Retrospective Study
NCT06085456 ·Status: RECRUITING
-
Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer
NCT06907771 ·Status: RECRUITING
-
Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer
NCT06019923 ·Status: RECRUITING
-
Surgery for Relapsed Ovarian Cancer in Precision
NCT06602063 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer
NCT05206890 ·Status: RECRUITING
-
Administration of Hyperthermic Intraperitoneal Chemotherapy in the General Ward
NCT06277947 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
NCT06522828 ·Status: RECRUITING ·Phase: PHASE2
-
Exploratory Study on HER2 Detection Method and Positive Threshold for High-grade Serous Adenocarcinoma of the Ovary
NCT06883487 ·Status: RECRUITING
-
The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer
NCT04582552 ·Status: UNKNOWN
-
Study of DP303c Injection in Patients With Advanced Ovarian Cancer
NCT04828616 ·Status: UNKNOWN ·Phase: PHASE2
-
Microvascular Ultrasonographic Imaging for the Detection of Early Stage Epithelial Ovarian Carcinoma
NCT00531570 ·Status: COMPLETED
-
Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma
NCT06969833 ·Status: RECRUITING ·Phase: NA
-
The Culture of Ovarian Cancer Organoids and Drug Screening
NCT04768270 ·Status: UNKNOWN
-
Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands
NCT07039552 ·Status: RECRUITING
-
First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer
NCT01669226 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer
NCT07125391 ·Status: RECRUITING ·Phase: PHASE2